keyword
MENU ▼
Read by QxMD icon Read
search

"Clostridium difficile" "prevention"

keyword
https://www.readbyqxmd.com/read/28810021/bezlotoxumab-zinplava-for-prevention-of-recurrent-clostridium-difficile-infection
#1
(no author information available yet)
No abstract text is available yet for this article.
August 15, 2017: JAMA: the Journal of the American Medical Association
https://www.readbyqxmd.com/read/28805081/bezlotoxumab-for-the-prevention-of-clostridium-difficile-recurrence
#2
Antoine Couture-Cossette, Alex Carignan, Subburaj Ilangumaran, Louis Valiquette
Clostridium difficile infection is a major economic and clinical burden, due to its high frequency of recurrence. Currently recommended treatments are not efficient for prevention and may contribute to the risk of recurrent infection. In recent years, research has focused on strategies to lessen this risk. Bezlotoxumab is a monoclonal antibody that prevents recurrences of C. difficile infection through the antagonism of toxin B. Areas covered: In this review, the authors discuss the burden of C. difficile infection and its recurrences, the mechanisms underlying the recurrences, and current C...
August 13, 2017: Expert Opinion on Biological Therapy
https://www.readbyqxmd.com/read/28801119/stability-and-efficacy-of-frozen-and-lyophilized-fecal-microbiota-transplant-fmt-product-in-a-mouse-model-of-clostridium-difficile-infection-cdi
#3
Zhi-Dong Jiang, Ashley Alexander, Shi Ke, Evangelia M Valilis, Shaofan Hu, Bingjie Li, Herbert L DuPont
Freezing donor fecal microbiota has simplified fecal microbiota transplantation (FMT) in the treatment of recurrent C. difficile infection (CDI). However, the optimal storage time for the frozen FMT products remains unknown. Using an established murine model of CDI, stability and efficacy of frozen and lyophilized FMT product was studied at time points from 2 months to 15 months. DNA was extracted from fecal samples from the mice with identification of specific bacterial species by real-time quantitative PCR (qPCR)...
August 9, 2017: Anaerobe
https://www.readbyqxmd.com/read/28779831/clostridium-difficile-infection
#4
REVIEW
John G Bartlett
Clostridium difficile infection is a major health care challenge in terms of patient and economic consequences. For the patient, it is a morbid and sometimes a life-threatening iatrogenic complication of antibiotic treatment. In the United States, the provider's institution may face financial penalties, because the Centers for Disease Control and Prevention views this as an iatrogenic health care-associated complication that may not be reimbursable by the Centers for Medicare and Medicaid Services; this has resulted in substantial incentives for new approaches to prevention and treatment...
September 2017: Infectious Disease Clinics of North America
https://www.readbyqxmd.com/read/28766951/therapy-for-clostridium-difficile-infection-any-news-beyond-metronidazole-and-vancomycin
#5
C F Manthey, L Eckmann, V Fuhrmann
Infections with Clostridium difficile (CDI) represent a major burden for the health care system. Treatment is generally by antibiotic therapy with metronidazole and vancomycin, but efficacy remains suboptimal. Areas covered: This review discusses established and emerging treatment options for CDI, and current therapeutic guidelines, taking into account disease severity and risk of relapse. Expert commentary: New therapeutic approaches, including antibodies and new classes of antibiotics, and new measures for preventing infection with vaccines are under development in phase II/III clinical trials...
August 11, 2017: Expert Review of Clinical Pharmacology
https://www.readbyqxmd.com/read/28761936/clostridium-difficile-colonizes-alternative-nutrient-niches-during-infection-across-distinct-murine-gut-microbiomes
#6
Matthew L Jenior, Jhansi L Leslie, Vincent B Young, Patrick D Schloss
Clostridium difficile is the largest single cause of hospital-acquired infection in the United States. A major risk factor for Clostridium difficile infection (CDI) is prior exposure to antibiotics, as they disrupt the gut bacterial community which protects from C. difficile colonization. Multiple antibiotic classes have been associated with CDI susceptibility, many leading to distinct community structures stemming from variation in bacterial targets of action. These community structures present separate metabolic challenges to C...
July 2017: MSystems
https://www.readbyqxmd.com/read/28760934/next-generation-probiotics-targeting-clostridium-difficile-through-precursor-directed-antimicrobial-biosynthesis
#7
Jennifer K Spinler, Jennifer Auchtung, Aaron Brown, Prapaporn Boonma, Numan Oezguen, Caná L Ross, Ruth Ann Luna, Jessica Runge, James Versalovic, Alex Peniche, Sara M Dann, Robert A Britton, Anthony Haag, Tor C Savidge
Integration of antibiotic and probiotic therapy has the potential to lessen the public health burden to antimicrobial-associated diseases. Clostridium difficile infection (CDI) represents an important example where rational design of next generation probiotics is being actively pursued to prevent disease recurrence. Because intrinsic resistance to clinically relevant CDI antibiotics (vancomycin, metronidazole, and fidaxomicin) is a desired trait in such probiotic species, we screened several bacteria and identified Lactobacillus reuteri as a promising candidate for adjunct therapy...
July 31, 2017: Infection and Immunity
https://www.readbyqxmd.com/read/28756805/burden-of-clostridium-difficile-infections-in-french-hospitals-in-2014-from-the-national-health-insurance-perspective
#8
Soline Leblanc, Cécile Blein, Antoine Andremont, Pierre-Alain Bandinelli, Thibaut Galvain
OBJECTIVE To describe the hospital stays of patients with Clostridium difficile infection (CDI) and to measure the hospitalization costs of CDI (as primary and secondary diagnoses) from the French national health insurance perspective DESIGN Burden of illness study SETTING All acute-care hospitals in France METHODS Data were extracted from the French national hospitalization database (PMSI) for patients covered by the national health insurance scheme in 2014. Hospitalizations were selected using the International Classification of Diseases, 10 th revision (ICD-10) code for CDI...
August 2017: Infection Control and Hospital Epidemiology
https://www.readbyqxmd.com/read/28747822/beneficial-effect-of-bifidobacterium-longum-atcc-15707-on-survival-rate-of-clostridium-difficile-infection-in-mice
#9
Bohyun Yun, Minyu Song, Dong-June Park, Sejong Oh
Clostridium difficile infection (CDI) is the main cause of hospital-acquired diarrhea that can cause colitis or even death. The medical-treatment cost and deaths caused by CDI are increasing annually worldwide. New approaches for prevention and treatment of these infections are needed, such as the use of probiotics. Probiotics, including Bifidobacterium spp. and Lactobacillus, are microorganisms that confer a health benefit to the host when administered in adequate amounts. The effect of Bifidobacterium longum ATCC 15707 on infectious disease caused by C...
2017: Korean Journal for Food Science of Animal Resources
https://www.readbyqxmd.com/read/28747178/anaerobic-bacteria-growth-in-the-presence-of-cathelicidin-ll-37-and-selected-ceragenins-delivered-as-magnetic-nanoparticles-cargo
#10
Bonita Durnaś, Ewelina Piktel, Marzena Wątek, Tomasz Wollny, Stanisław Góźdź, Jolanta Smok-Kalwat, Katarzyna Niemirowicz, Paul B Savage, Robert Bucki
BACKGROUND: Cationic antibacterial peptides (CAPs) and synthetic molecules mimicking the amphiphilic structure of CAPs, such as ceragenins, are promising compounds for the development of new antimicrobials. RESULTS: We tested the in vitro activity of ceragenins CSA-13 and CSA-131 against several anaerobic bacteria including Bacteroides spp. and Clostridium difficile. We compared results to the activity of cathelicidin LL-37, metronidazole and nanosystems developed by attachment of CSA-13 and CSA-131 to magnetic nanoparticles (MNPs)...
July 26, 2017: BMC Microbiology
https://www.readbyqxmd.com/read/28739791/protection-of-hamsters-from-mortality-by-reducing-fecal-moxifloxacin-concentration-with-dav131a-in-a-model-of-moxifloxacin-induced-clostridium-difficile-colitis
#11
Charles Burdet, Sakina Sayah-Jeanne, Thu Thuy Nguyen, Christine Miossec, Nathalie Saint-Lu, Mark Pulse, William Weiss, Antoine Andremont, France Mentré, Jean de Gunzburg
BACKGROUND: Lowering the gut exposure to antibiotics during treatments can prevent microbiota disruption. We evaluated the effect of an activated charcoal-based adsorbent, DAV131A, on fecal free moxifloxacin concentration and mortality in a hamster model of moxifloxacin-induced C. difficile infection. METHODS: 215 hamsters receiving moxifloxacin subcutaneously (D1-D5) were orally infected at D3 with C. difficile spores. They received various doses (0-1800mg/kg/day) and schedules (BID, TID) of DAV131A (D1-D8)...
July 24, 2017: Antimicrobial Agents and Chemotherapy
https://www.readbyqxmd.com/read/28730660/bezlotoxumab-a-novel-agent-for-the-prevention-of-recurrent-clostridium-difficile-infection
#12
Wesley D Kufel, Aaron S Devanathan, Ashley H Marx, David J Weber, Lindsay M Daniels
Over the last decade, the incidence and severity of Clostridium difficile infection (CDI) have significantly increased, leading to a rise in CDI-associated hospitalizations, health care costs, and mortality. Although treatment options exist for CDI, recurrence is frequent following treatment. Furthermore, patients with at least one CDI recurrence are at an increased risk of developing additional recurrences. A novel approach to the prevention of recurrent CDI is the use of monoclonal antibodies directed against the toxins responsible for CDI as an adjunct to antibiotic treatment...
July 21, 2017: Pharmacotherapy
https://www.readbyqxmd.com/read/28712463/vaccines-in-development-for-the-primary-prevention-of-clostridium-difficile-infection
#13
Laurel M Legenza, Susanne G Barnett, Warren E Rose
No abstract text is available yet for this article.
July 2017: Journal of the American Pharmacists Association: JAPhA
https://www.readbyqxmd.com/read/28705932/use-of-a-neutralizing-antibody-helps-identify-structural-features-critical-for-binding-of-clostridium-difficile-toxin-tcda-to-the-host-cell-surface
#14
Heather K Kroh, Ramyavardhanee Chandrasekaran, Kim Rosenthal, Rob Woods, Xiaofang Jin, Melanie D Ohi, Andrew C Nyborg, G Jonah Rainey, Paul Warrener, Benjamin W Spiller, D Borden Lacy
Clostridium difficile is a clinically significant pathogen that causes mild-to-severe (and often recurrent) colon infections. Disease symptoms stem from the activities of two large, multi-domain toxins known as TcdA and TcdB. The toxins can bind, enter, and perturb host cell function through a multi-step mechanism of receptor binding, endocytosis, pore formation, autoproteolysis, and glucosyltransferase-mediated modification of host substrates. Monoclonal antibodies that neutralize toxin activity provide a survival benefit in preclinical animal models and prevent recurrent infections in human clinical trials...
July 13, 2017: Journal of Biological Chemistry
https://www.readbyqxmd.com/read/28705583/prevalence-and-risk-factors-for-colonization-by-clostridium-difficile-and-extended-spectrum-%C3%AE-lactamase-producing-enterobacteriaceae-in-rehabilitation-clinics-in-germany
#15
Mardjan Arvand, Claudia Ruscher, Gudrun Bettge-Weller, Markus Goltz, Yvonne Pfeifer
BACKGROUND: Rehabilitation clinics may vary widely in terms of type of care provided, duration of hospital stay, and case severity. Only few data are available on prevalence of Clostridium difficile or extended-spectrum β-lactamase-producing Enterobacteriaceae (ESBL-E) colonization in rehabilitation clinics in Germany. AIM: This study investigated the frequency of intestinal colonization by these pathogens among patients in rehabilitation clinics of different specialization...
July 10, 2017: Journal of Hospital Infection
https://www.readbyqxmd.com/read/28704538/intestinal-calcium-and-bile-salts-facilitate-germination-of-clostridium-difficile-spores
#16
Travis J Kochan, Madeline J Somers, Alyssa M Kaiser, Michelle S Shoshiev, Ada K Hagan, Jessica L Hastie, Nicole P Giordano, Ashley D Smith, Alyxandria M Schubert, Paul E Carlson, Philip C Hanna
Clostridium difficile (C. difficile) is an anaerobic gram-positive pathogen that is the leading cause of nosocomial bacterial infection globally. C. difficile infection (CDI) typically occurs after ingestion of infectious spores by a patient that has been treated with broad-spectrum antibiotics. While CDI is a toxin-mediated disease, transmission and pathogenesis are dependent on the ability to produce viable spores. These spores must become metabolically active (germinate) in order to cause disease. C. difficile spore germination occurs when spores encounter bile salts and other co-germinants within the small intestine, however, the germination signaling cascade is unclear...
July 2017: PLoS Pathogens
https://www.readbyqxmd.com/read/28692690/risk-of-surgical-site-infection-acute-kidney-injury-and-clostridium-difficile-infection-following-antibiotic-prophylaxis-with-vancomycin-plus-a-beta-lactam-versus-either-drug-alone-a-national-propensity-score-adjusted-retrospective-cohort-study
#17
MULTICENTER STUDY
Westyn Branch-Elliman, John E Ripollone, William J O'Brien, Kamal M F Itani, Marin L Schweizer, Eli Perencevich, Judith Strymish, Kalpana Gupta
BACKGROUND: The optimal regimen for perioperative antimicrobial prophylaxis is controversial. Use of combination prophylaxis with a beta-lactam plus vancomycin is increasing; however, the relative risks and benefits associated with this strategy are unknown. Thus, we sought to compare postoperative outcomes following administration of 2 antimicrobials versus a single agent for the prevention of surgical site infections (SSIs). Potential harms associated with combination regimens, including acute kidney injury (AKI) and Clostridium difficile infection (CDI), were also considered...
July 2017: PLoS Medicine
https://www.readbyqxmd.com/read/28688849/clostridium-difficile-infection-in-contemporary-urologic-practice
#18
REVIEW
Jonathan E Heinlen, Linda Salinda, Michael S Cookson
Clostridium difficile infection (CDI) is a high-impact hospital acquired condition and chief driver of excess morbidity, mortality, and treatment cost. Diagnosis, treatment, and prevention of clostridium difficile infection is key component of any hospital based practice. Urologists see a small percentage of all patients with CDI, however they traditionally utilize antibiotic agents that put patients at risk for CDI. Urologic procedures making use of bowel have a significantly higher rate of CDI than other procdures...
July 5, 2017: Urology
https://www.readbyqxmd.com/read/28675267/-antimicrobials-some-practical-considerations
#19
Nadine Ngatchou, Véronique Masserey-Bonvin, Niels Gobin, Luc Barberini
Antibiotics are frequently prescribed in hospitalized and in outpatients. We review four important aspects for their daily prescription. In elderly patients, the prescription should take into account changes in the volume of distribution and the usual decline in renal function even in the absence of chronic kidney disease. Particular antibiotics can trigger infection with Clostridium difficile. We discuss actual and novel strategies for its prevention. Renal toxicity of antibiotics includes acute tubular necrosis, interstitial nephritis and crystals obstructing renal tubule, depending on the class of antibiotics...
September 7, 2016: Revue Médicale Suisse
https://www.readbyqxmd.com/read/28669616/clostridium-difficile-chimeric-toxin-receptor-binding-domain-vaccine-induced-protection-against-different-strains-in-active-and-passive-challenge-models
#20
Jing-Hui Tian, Gregory Glenn, David Flyer, Bin Zhou, Ye Liu, Eddie Sullivan, Hua Wu, James F Cummings, Larry Elllingsworth, Gale Smith
Clostridium difficile is the number one cause of nosocomial antibiotic-associated diarrhea in developed countries. Historically, pathogenesis was attributed two homologous glucosylating toxins, toxin-A (TcdA) and toxin-B (TcdB). Over the past decade, however, highly virulent epidemic strains of C. difficile (B1/NAP1/027) have emerged and are linked to an increase in morbidity and mortality. Increased virulence is attributed to multiple factors including: increased production of A- and B-toxins; production of binary toxin (CDT); and the emergence of more toxic TcdB variants (TcdB(027))...
July 24, 2017: Vaccine
keyword
keyword
95484
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"